GASTROESOPHAGEAL CANCER
Clinical trials for GASTROESOPHAGEAL CANCER explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL CANCER trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug cocktail aims to shrink Hard-to-Treat stomach cancers
Disease control CompletedThis phase 2 trial tests whether combining two drugs—cabozantinib and pembrolizumab—can slow or stop the growth of advanced gastric or gastroesophageal cancer. The study enrolls people whose cancer has worsened despite at least one prior chemotherapy treatment. Researchers will m…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New combo attack on stomach cancer shows promise in small trial
Disease control CompletedThis phase 2 trial tested a combination of radiation, a targeted drug (olaparib), and an immunotherapy (pembrolizumab) in 9 people with advanced stomach or gastroesophageal junction cancer that had spread. The goal was to see if this approach could shrink tumors that were not dir…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase: PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New combo therapy shows promise for Tough-to-Treat stomach cancer
Disease control CompletedThis pilot study tested a combination of chemotherapy drugs (FOLFIRINOX plus paclitaxel and carboplatin) along with proton beam radiation before surgery in 25 people with gastroesophageal cancer. The goal was to see if this intense pre-surgery treatment could shrink tumors and be…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy shows promise in advanced cancer trial
Disease control CompletedThis early-phase study tested a new drug called gevokizumab alongside standard cancer treatments in 167 adults with advanced colorectal, stomach, or kidney cancer that had spread. The goal was to find a safe and active dose and see if the combination could help control the diseas…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Can adding radiation before surgery help stomach cancer patients live longer?
Disease control CompletedThis study tested whether adding radiation to chemotherapy before surgery improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 204 adults with operable tumors received either chemotherapy alone or chemotherapy plus radiation before…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase: PHASE3 • Sponsor: Shanghai Cancer Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy-Chemo cocktail aims to tame stomach cancer
Disease control CompletedThis Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:47 UTC
-
New remote nutrition program aims to help cancer patients during treatment
Symptom relief CompletedThis study tests a program that provides remote nutrition counseling and uses a Fitbit to track activity and diet for people with gastroesophageal cancer. Participants log their food intake and meet with a dietitian via video calls. The goal is to see if this approach is practica…
Matched conditions: GASTROESOPHAGEAL CANCER
Phase: NA • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Drain fluid may hold key to immunotherapy response in gastroesophageal cancer
Knowledge-focused CompletedThis completed study collected surgical drain fluid and blood from 10 patients who had surgery for stomach or esophageal cancer. Researchers analyzed these samples for molecular markers that might predict how well a patient would respond to immunotherapy. The goal was to establis…
Matched conditions: GASTROESOPHAGEAL CANCER
Sponsor: Inova Health Care Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC